Depth: the pharmaceutical industry, the five major changes that are taking place

Categories:Industry News
Time of issue:2021-10-14 17:16

(Summary description)In the past, the success of pharmaceutical companies relied on the “R&D + marketing” two-wheel drive. A good product reserve and marketing model can achieve good business.





Depth: the pharmaceutical industry, the five major changes that are taking place

(Summary description)In the past, the success of pharmaceutical companies relied on the “R&D + marketing” two-wheel drive. A good product reserve and marketing model can achieve good business.

Categories:Industry News
Time of issue:2021-10-14 17:16
Views:

Information

In the past,the success of pharmaceutical companies relied on the “R&D + marketing” two-wheel drive. A good product reserve and marketing model can achieve good business. However, under the new competitive environment, the difficulty of research and development is increasing day by day. The marketing model is the same. The two legs of R&D and marketing alone are not going to win the industry acceleration period.

To achieve leap-forward growth in pharmaceutical companies, the driving model must be upgraded and upgraded. The future leading the breakthrough of pharmaceutical companies will be the four-wheel drive model of “R&D + marketing + capital + mechanism”, in which capital and mechanism will be the new driving force for enterprise development .

Capital: At present, most pharmaceutical companies in China still stay in the industrial stage. Enterprises that don't understand capital are like the old oxen arable land. It is not enough to bury itself in the industry. The combination of capital and industry can release huge forces to promote the development of enterprises. Pharmaceutical enterprises must learn to use capital means to integrate high-quality resources, including product resources, brand resources, network resources, and human resources.

Listed companies must be more courageous and take steps to achieve a positive interaction between industry and capital. Non-listed companies should also be more open, unable to get on the new board on the main board, and look for capital opportunities in the multi-tier capital market.

Mechanism: The development of pharmaceutical enterprises is still subject to the bottleneck of key talents, especially leading talents. In our consulting projects, many entrepreneurs are struggling to find key talent. Many examples also prove that attracting talents by simply hiring professional managers or using traditional salary has far failed to achieve the desired results. The end result is often the gathering of wealthy people and the scattered people.

I think that if enterprises want to successfully introduce key talents, they should first solve the mechanism problem. Use mechanisms to attract key talents, use mechanisms to unlock employee motivation, and use mechanisms to drive business development. We have repeatedly stressed that the innovation mechanism is worthy of every pharmaceutical company to try, such as incremental profit sharing, stock retention income incremental conversion, project and investment performance gambling, partner plans, incentive funds and so on .

Scan the QR code to read on your phone

Previous: The purchase price of medical equipment streaking officially began, and competitors reported more violently!

Next: Hematopoietic stem cell "brake system" can intervene or prevent leukemia

Previous: The purchase price of medical equipment streaking officially began, and competitors reported more violently!

Next: Hematopoietic stem cell "brake system" can intervene or prevent leukemia